Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Beximco looks beyond Bangladesh with $6.6 sofosbuvir

This article was originally published in Scrip

Executive Summary

Bangladesh's Beximco Pharmaceuticals may not be the first onto the local market with its cut-price version of Gilead's hepatitis C blockbuster Sovaldi (sofosbuvir), but the company appears to be pulling out all the stops to establish a stronghold in the market.

Advertisement

Related Content

Bangladesh HCV Market: Can Generic Epclusa Shake Things Up?

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC029120

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel